In March 2025, the European Commission proposed the Critical Medicines Act to improve the availability, supply, and production of critical medicines within the EU. This legislative initiative aims to ensure the sustainable availability, supply, and production of critical medicines within the European Union.
The proposal comes in response to increasing concerns over Europe’s reliance on third countries especially China and India for essential medicines and active pharmaceutical ingredients. The Critical Medicines Act introduces a robust framework to reduce vulnerabilities in the supply chain and improve access to life-saving medicines across all EU member states.
Key components of the Act include:
- Designation of Strategic Projects to boost EU-based manufacturing of critical medicines and ingredients, with faster approval procedures and access to EU funding.
- Revised Procurement Guidelines encouraging national authorities to factor in supply security and resilience—not just pricing—when awarding contracts for generic medicines.
- Joint Procurement Initiatives allow EU countries to purchase critical medicines together, ensuring fairer distribution and stronger bargaining power.
- Global Partnerships aimed at diversifying the EU’s medicine supply sources through collaboration with like-minded countries.
Critical Medicines Act 2025
The CMA complements the broader European Health Union strategy, reinforcing the EU’s commitment to a stronger, more independent pharmaceutical sector that serves public health efficiently and equitably.
As a stakeholder in the pharmaceutical supply chain, MVS Pharma GmbH supports this progressive step toward ensuring stable and long-term access to critical medicines within Europe.
Disclaimer:
As a service to our readers, MVS Pharma GmbH publishing provides access to our library of archived content in our blog. Please note the date of the last review or update on all articles. No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
MVS Pharma GmbH will soon be launching an omega-3 dietary supplement onto the European market that has been developed for the highest quality standards in terms of oxidation avoidance and, therefore greatest bioavailability. In addition, in vitro studies are currently underway at the University of Ulm, in which Professor Dr. Rüdiger Groß tested a patented mouth and nose spray (Virudol) that can eliminate various flu viruses based on natural substances. In addition, MVS has a wholesale license and has specialized in sourcing much-needed medicines such as Amoxicillin, Salbutamol, etc. from India through its local branch with a focus on local quality and safety testing, compliance with international GMP regulations and the highest quality level of user security (examples of local language brochures, identical units of measurement, batch control and full tracking, etc).
